<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625586</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000587562</org_study_id>
    <secondary_id>RAVENBIO-RV12-2007-003</secondary_id>
    <nct_id>NCT00625586</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase 2 Evaluation of the Monoclonal Antibody, RAV12, in Combination With Standard Gemcitabine in the Treatment of Patients With Metastatic Pancreatic Cancer Who Have Not Been Previously Treated for Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways.&#xD;
      Some block the ability of tumor cells to grow and spread. Others find tumor cells and help&#xD;
      kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving RAV12 together with gemcitabine may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and best dose of monoclonal&#xD;
      antibody RAV12 when given together with gemcitabine in treating patients with metastatic&#xD;
      pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the maximum tolerated dose of monoclonal antibody RAV12 when administered&#xD;
           with standard gemcitabine hydrochloride in patients with previously untreated metastatic&#xD;
           pancreatic cancer.&#xD;
&#xD;
        -  To determine the proportion of these patients surviving at 8 months after initiation of&#xD;
           this regimen.&#xD;
&#xD;
        -  To provide point estimates for response rate and duration of response in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  To define the toxicity profile of this drug in these patients when administered with&#xD;
           standard gemcitabine hydrochloride.&#xD;
&#xD;
        -  To estimate, preliminarily, the progression-free survival and overall survival of these&#xD;
           patients after treatment with this regimen.&#xD;
&#xD;
        -  To explore the utility of the tumor marker, carbohydrate antigen 19-9 (CA19-9), in the&#xD;
           assessment of these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of monoclonal antibody RAV12, followed by an&#xD;
      efficacy study. The study is conducted in two segments.&#xD;
&#xD;
        -  Segment 1 (dose escalation of RAV12): Patients receive gemcitabine hydrochloride IV over&#xD;
           30 minutes on days 1, 8, 15, and 22 of course 1 and on days 1, 8, and 15 of each&#xD;
           subsequent course. Patients also receive RAV12 IV once weekly on days 1, 8, and 15 or&#xD;
           twice weekly on days 1, 4 or 5, 8, 11 or 12, 15, and 18 or 19 until the maximum&#xD;
           tolerated dose (MTD) is reached. Treatment repeats every 28 days in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Segment 2 (efficacy): Once the MTD has been determined, patients receive RAV12 at the&#xD;
           MTD and gemcitabine hydrochloride as in segment 1. Treatment repeats every 28 days in&#xD;
           the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are obtained for pharmacokinetic sampling during the dose-escalation segment of&#xD;
      the study. Samples are analyzed to determine plasma concentrations of RAV12, gemcitabine&#xD;
      hydrochloride, and difluorodeoxyuridine. Blood samples are also examined periodically for&#xD;
      expression of serum biomarkers (i.e., CA19-9, RAAG12, and HACA) and for DNA analysis of&#xD;
      Fc-gamma receptor polymorphisms. Archival paraffin blocks or slides from biopsy of primary or&#xD;
      metastatic deposit or fresh/frozen tissue may be obtained at baseline for additional&#xD;
      correlative studies. Samples are analyzed by immunohistochemistry (IHC) for expression of&#xD;
      RAAG12 and for development of a companion RAAG12 diagnostic assay.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 8 weeks for up to 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue a total of 18 patients in the dose-escalation&#xD;
      segment and 63 patients in the efficacy segment of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Corporate decision&#xD;
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Alive at 8 Months</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Alive at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response and Complete Response Rates</measure>
    <time_frame>8 months</time_frame>
    <description>Based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.0; partial response = 30% decrease in sum of longest diameter. complete response = 100% decrease in sum of longest diameter. Rate of response = proportion of complete or partial responses based on number of patients evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>time to progression or death, up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>any timeframe following study drug up to 3 years</time_frame>
    <description>Frequency of adverse events and serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>29 days</time_frame>
    <description>RAV12 and gemcitabine cmax</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>RAV12 plus gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RAV12 plus gemcitabine</intervention_name>
    <description>Initial dose of gemcitabine plus RAV12 at 0.375 mg/kg qw escalated to 0.75 mg/kg qw.&#xD;
During the efficacy segment, 63 pts were to be treated with gemcitabine 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days plus RAV12 at Maximum Tolerated Dose (MTD) iv days 1; 4 or 5; 8, 11 or 12; and 15, 18 or 19 of each 28-day cycle until progression.</description>
    <arm_group_label>RAV12 plus gemcitabine</arm_group_label>
    <other_name>gemcitabine: Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
                    -  No prior therapy for metastatic disease (except prior adjuvant chemotherapy&#xD;
                       and/or radiotherapy)&#xD;
&#xD;
          -  At least 1 radiographically measurable site of disease ≥ 2 cm in the largest dimension&#xD;
             by traditional CT technique or ≥ 1 cm by spiral CT scan (per RECIST)&#xD;
&#xD;
          -  No known history of current or prior central nervous system (CNS) metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase and γ-glutamyltransferase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Amylase and lipase ≤ 1.5 times ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must be available for study-related treatments and assessments at the treating&#xD;
             institution&#xD;
&#xD;
          -  No known hypersensitivity to any component of gemcitabine hydrochloride&#xD;
&#xD;
          -  No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any&#xD;
             excipient contained in the drug formulation&#xD;
&#xD;
          -  No other primary malignancy that has been in remission for ≤ 3 years except treated&#xD;
             nonmelanoma skin cancer, biopsy-confirmed carcinoma in situ of the cervix, squamous&#xD;
             intraepithelial lesion on Papanicolaou smear, localized prostate cancer with Gleason&#xD;
             score &lt; 6, or resected melanoma in situ&#xD;
&#xD;
          -  No other primary malignancy that has a generally accepted recurrence risk ≥ 10%&#xD;
&#xD;
          -  No active viral, bacterial, or systemic fungal infection requiring parenteral&#xD;
             treatment within 4 weeks of enrollment&#xD;
&#xD;
          -  No history of chronic or recurrent infections that require continuous use of&#xD;
             antiviral, antifungal, or antibacterial agents&#xD;
&#xD;
          -  No serious underlying medical condition that would impair the patient's ability to&#xD;
             receive or tolerate the planned treatment at the investigational site, including&#xD;
             significant pulmonary compromise or heart disease of New York Heart Association class&#xD;
             III or IV&#xD;
&#xD;
          -  No dementia or altered mental status that would preclude sufficient understanding to&#xD;
             provide informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  More than 4 weeks since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  More than 1 week since prior oral antiviral, antifungal, or antibacterial therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive medications, steroids (except steroid inhaler,&#xD;
             ophthalmic solution, nasal spray, or a stable dose of ≤ 10 mg/day of oral prednisone&#xD;
             or equivalent), other antineoplastic therapy, or antitumor vaccinations&#xD;
&#xD;
          -  Monoclonal antibody treatment for non-cancer indications must be completed at least 3&#xD;
             half lives from study entry&#xD;
&#xD;
          -  No concurrent prophylactic hematologic growth factors&#xD;
&#xD;
          -  No concurrent megavitamin therapy&#xD;
&#xD;
          -  No concurrent bisphosphonates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanford Stewart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MacroGenics, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MacroGenics, Incorporated</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <results_first_submitted>August 20, 2012</results_first_submitted>
  <results_first_submitted_qc>November 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2012</results_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient recruitment was conducted by two cancer institutes between April and June 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RAV12 Plus Gemcitabine</title>
          <description>RAV12 monoclonal antibody plus gemcitabine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RAV12 Plus Gemcitabine</title>
          <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="NA">Only 2 patients enrolled. Statistical analysis not performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Alive at 12 Months</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAV12 Plus Gemcitabine</title>
            <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Alive at 12 Months</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Response and Complete Response Rates</title>
        <description>Based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.0; partial response = 30% decrease in sum of longest diameter. complete response = 100% decrease in sum of longest diameter. Rate of response = proportion of complete or partial responses based on number of patients evaluated.</description>
        <time_frame>8 months</time_frame>
        <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>RAV12 Plus Gemcitabine</title>
            <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response and Complete Response Rates</title>
          <description>Based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.0; partial response = 30% decrease in sum of longest diameter. complete response = 100% decrease in sum of longest diameter. Rate of response = proportion of complete or partial responses based on number of patients evaluated.</description>
          <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>time to progression or death, up to 3 years</time_frame>
        <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>RAV12 Plus Gemcitabine</title>
            <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>three years</time_frame>
        <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>RAV12 Plus Gemcitabine</title>
            <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Frequency of adverse events and serious adverse events</description>
        <time_frame>any timeframe following study drug up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAV12 Plus Gemcitabine</title>
            <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Frequency of adverse events and serious adverse events</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>RAV12 and gemcitabine cmax</description>
        <time_frame>29 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RAV12 Plus Gemcitabine</title>
            <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>RAV12 and gemcitabine cmax</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Alive at 8 Months</title>
        <time_frame>8 months</time_frame>
        <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>RAV12 Plus Gemcitabine</title>
            <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Alive at 8 Months</title>
          <population>Study was terminated after 2 patients enrolled therefore no statistical analyses were performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RAV12 Plus Gemcitabine</title>
          <description>Escalating doses of RAV12, plus standard gemcitabine at 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization with Grade 3 rash and leg pain; Grade 2 edema</sub_title>
                <description>Pt. hospitalized 2 days after second infusions. Events considered related to gemcitabine. Pt. discontinued from study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urine colour abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 2 patients enrolled in the trial. Both were evaluable for safety and only one was evaluable for efficacy. No statistical analyses were performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sr. Director of Clinical Operations</name_or_title>
      <organization>MacroGenics, Inc.</organization>
      <phone>650 624 2676</phone>
      <email>baughmanj@macrogenics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

